

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHERISH SUNSHINE INTERNATIONAL LIMITED

承輝國際有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 1094)

**(1) CHANGE OF DIRECTORS;
(2) RESIGNATION OF CHIEF FINANCIAL OFFICER;
(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND
(4) CHANGE OF AUTHORISED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Directors**”) of Cherish Sunshine International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the followings:

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The Board announces that Mr. Sze Kam Shing Alan (“**Mr. Sze**”) has resigned as an executive Director and the chief financial officer of the Company, with effect from 19 March 2026. Mr. Sze shall remain as the company secretary of the Company and the authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Sze tendered his resignation as he would like to devote more time to his other business commitment. Mr. Sze has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Deng Hua (“**Ms. Deng**”) has resigned as an independent non-executive Director, the chairman of each of the nomination committee of the Board (the “**Nomination Committee**”) and remuneration committee of the Board (the “**Remuneration Committee**”), and a member of the audit committee of the Board (the “**Audit Committee**”), with effect from 19 March 2026.

Ms. Deng tendered her resignation as she would like to devote more time to her other business commitment. Ms. Deng has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Wang Xiaoqiong (“**Ms. Wang**”) has been appointed as an independent non-executive Director, a member of each of the Nomination Committee, Remuneration Committee and Audit Committee with effect from 19 March 2026. Set out below are the biographical details of Ms. Wang:

Ms. Wang Xiaoqiong, aged 40, has over 15 years of experience in finance and accounting. She obtained a Master of Business Administration from Southwestern University of Finance and Economics in 2018. Ms. Wang is currently a director and overseas business director of Hemos (Chongqing) Medical Biotechnology Co., Ltd. Prior to this, Ms. Wang worked in (i) finance department of HNA Group headquarter and international headquarter as head of financing and deputy general manager from June 2007 to January 2015; (ii) AID Life Science, a company listed on the GEM of the Stock Exchange (Stock Code: 8088) and subsequently delisted, as deputy financial controller from October 2015 to June 2016; (iii) Tysan Holdings Limited, a company listed on the main board of the Stock Exchange (Stock Code: 687), as financial controller from July 2016 to December 2019; and (iv) China Shun Ke Long Holdings Limited, a company listed on the main board of the Stock Exchange (Stock Code: 974), as deputy president from January 2020 to July 2020. Ms. Wang is a member of the Institute of Public Accountants, Australia, an Intermediate Economist in the PRC and a Senior International Finance Manager certified by the International Finance Management Association.

Ms. Wang has entered into a formal service contract with the Company as an independent non-executive Director for a term of three years commencing from 19 March 2026, subject to retirement by rotation and re-election at the general meeting of the Company in accordance with the bye-laws of the Company. Ms. Wang is entitled to a monthly director’s fee of HK\$10,000, which is determined by the Board with reference to her experience, duties and responsibilities in the Company as well as the current market conditions.

Save as disclosed above, Ms. Wang (i) does not hold any other position with the Company or other members of the Group, or any other major appointment or professional qualification as at the date of this announcement; (ii) does not hold any directorship in other publicly listed companies in Hong Kong or overseas in the last three years nor have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (iii) does not have any interest in the listed securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance as at the date of this announcement.

Ms. Wang has confirmed that (i) she meets the criteria for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, the Company is not aware of any matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to the appointment of Ms. Wang, and there is no other information relating to Ms. Wang which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

APPOINTMENT OF CHAIRMAN OF NOMINATION COMMITTEE AND REMUNERATION COMMITTEE OF THE BOARD

The Board is pleased to announce that Mr. Zhao Zhijiao (“**Mr. Zhao**”), an independent non-executive director of the Company and a Joint Chairman of the Board, has been appointed as the chairman of Nomination Committee and Remuneration Committee with effect from 19 March 2026.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board announces that Mr. Lau Man Kit (“**Mr. Lau**”) has resigned as the authorised representative of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Companies Ordinance Authorised Representative**”) with effect from 19 March 2026.

Mr. Lau tendered his resignation as he would like to devote more time to his other business commitment. Mr. Lau has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that following the resignation of Mr. Lau from the abovementioned position, Mr. Sze has been appointed as the Companies Ordinance Authorised Representative with effect from 19 March 2026.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Sze and Ms. Deng for their valuable contributions to the Company during their tenure of services. The Board would also like to welcome Ms. Wang for joining the Board and Mr. Zhao on his new position as the chairman of Nomination Committee and Remuneration Committee.

By order of the Board
Cherish Sunshine International Limited
Yang Hua
Joint Chairman and Chief Executive

Hong Kong, 19 March 2026

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Yang Hua (Joint Chairman and Chief Executive); one non-executive Director, namely Mr. Ng Siu Hong; and three independent non-executive Directors, namely Mr. Zhao Zhijiao (Joint Chairman), Mr. He Zhi and Ms. Wang Xiaoqiong.